Evaluation effectiveness of 0.1% nepafenac on injection-related pain in patients undergoing intravitreal Ozurdex injection

Purpose: To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection. Methods: This prospective, randomized, double-blind placebo-controlled study included 59 patients who were diagnosed with retinal vein occlusion or pseudophakic cystoid macular edema a...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic advances in ophthalmology Vol. 11; p. 2515841419861856
Main Authors Ogurel, Tevfik, Ogurel, Reyhan, Ozkal, Fatma, Ölmez, Yaşar, Örnek, Nurgül, Onaran, Zafer
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.01.2019
Sage Publications Ltd
SAGE Publishing
Subjects
Age
Analgesics
Anesthesia
Diabetes
Diabetic retinopathy
Disease
Drug delivery systems
Edema
Eye surgery
Injections
Macular degeneration
Nonsteroidal anti-inflammatory drugs
Original Research
Pain
Womens health
United States > US
nepafenac
pain
intravitreal injection
Ozurdex
Online AccessGet full text
ISSN2515-8414
2515-8414
DOI10.1177/2515841419861856

Cover

Abstract Purpose: To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection. Methods: This prospective, randomized, double-blind placebo-controlled study included 59 patients who were diagnosed with retinal vein occlusion or pseudophakic cystoid macular edema and were selected to receive intravitreal Ozurdex injection. The patients were divided into two groups. Group 1, consisting of 31 eyes of 31 patients, received topical 0.1% nepafenac with topical anesthesia (0.5% proparacaine HCl, Alcaine; Alcon, TX, USA), and group 2, consisting of 28 eyes of 28 patients, received placebo with topical anesthesia. Results: There were 14 (45.2%) men and 17 (54.8%) women in group 1 and 16 (57.1%) men and 12 (42.9%) women in group 2. The mean age of the subjects was 64.42 ± 5.51 years in group 1 and 62.32 ± 7.54 years in group 2. The median visual analog scale pain score was 2 (1–3) in group 1 and 4 (1–6) in group 2. The visual analog scale pain score was significantly lower in group 1 than in group 2 (p < 0.001). Conclusion: Topical 0.1% nepafenac has an additive analgesic effect when combined with topical anesthesia for intravitreal Ozurdex injection.
AbstractList Purpose:To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection.Methods:This prospective, randomized, double-blind placebo-controlled study included 59 patients who were diagnosed with retinal vein occlusion or pseudophakic cystoid macular edema and were selected to receive intravitreal Ozurdex injection. The patients were divided into two groups. Group 1, consisting of 31 eyes of 31 patients, received topical 0.1% nepafenac with topical anesthesia (0.5% proparacaine HCl, Alcaine; Alcon, TX, USA), and group 2, consisting of 28 eyes of 28 patients, received placebo with topical anesthesia.Results:There were 14 (45.2%) men and 17 (54.8%) women in group 1 and 16 (57.1%) men and 12 (42.9%) women in group 2. The mean age of the subjects was 64.42 ± 5.51 years in group 1 and 62.32 ± 7.54 years in group 2. The median visual analog scale pain score was 2 (1–3) in group 1 and 4 (1–6) in group 2. The visual analog scale pain score was significantly lower in group 1 than in group 2 (p < 0.001).Conclusion:Topical 0.1% nepafenac has an additive analgesic effect when combined with topical anesthesia for intravitreal Ozurdex injection.
To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection. This prospective, randomized, double-blind placebo-controlled study included 59 patients who were diagnosed with retinal vein occlusion or pseudophakic cystoid macular edema and were selected to receive intravitreal Ozurdex injection. The patients were divided into two groups. Group 1, consisting of 31 eyes of 31 patients, received topical 0.1% nepafenac with topical anesthesia (0.5% proparacaine HCl, Alcaine; Alcon, TX, USA), and group 2, consisting of 28 eyes of 28 patients, received placebo with topical anesthesia. There were 14 (45.2%) men and 17 (54.8%) women in group 1 and 16 (57.1%) men and 12 (42.9%) women in group 2. The mean age of the subjects was 64.42 ± 5.51 years in group 1 and 62.32 ± 7.54 years in group 2. The median visual analog scale pain score was 2 (1-3) in group 1 and 4 (1-6) in group 2. The visual analog scale pain score was significantly lower in group 1 than in group 2 (  < 0.001). Topical 0.1% nepafenac has an additive analgesic effect when combined with topical anesthesia for intravitreal Ozurdex injection.
Purpose: To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection. Methods: This prospective, randomized, double-blind placebo-controlled study included 59 patients who were diagnosed with retinal vein occlusion or pseudophakic cystoid macular edema and were selected to receive intravitreal Ozurdex injection. The patients were divided into two groups. Group 1, consisting of 31 eyes of 31 patients, received topical 0.1% nepafenac with topical anesthesia (0.5% proparacaine HCl, Alcaine; Alcon, TX, USA), and group 2, consisting of 28 eyes of 28 patients, received placebo with topical anesthesia. Results: There were 14 (45.2%) men and 17 (54.8%) women in group 1 and 16 (57.1%) men and 12 (42.9%) women in group 2. The mean age of the subjects was 64.42 ± 5.51 years in group 1 and 62.32 ± 7.54 years in group 2. The median visual analog scale pain score was 2 (1–3) in group 1 and 4 (1–6) in group 2. The visual analog scale pain score was significantly lower in group 1 than in group 2 (p < 0.001). Conclusion: Topical 0.1% nepafenac has an additive analgesic effect when combined with topical anesthesia for intravitreal Ozurdex injection.
To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection.PURPOSETo evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection.This prospective, randomized, double-blind placebo-controlled study included 59 patients who were diagnosed with retinal vein occlusion or pseudophakic cystoid macular edema and were selected to receive intravitreal Ozurdex injection. The patients were divided into two groups. Group 1, consisting of 31 eyes of 31 patients, received topical 0.1% nepafenac with topical anesthesia (0.5% proparacaine HCl, Alcaine; Alcon, TX, USA), and group 2, consisting of 28 eyes of 28 patients, received placebo with topical anesthesia.METHODSThis prospective, randomized, double-blind placebo-controlled study included 59 patients who were diagnosed with retinal vein occlusion or pseudophakic cystoid macular edema and were selected to receive intravitreal Ozurdex injection. The patients were divided into two groups. Group 1, consisting of 31 eyes of 31 patients, received topical 0.1% nepafenac with topical anesthesia (0.5% proparacaine HCl, Alcaine; Alcon, TX, USA), and group 2, consisting of 28 eyes of 28 patients, received placebo with topical anesthesia.There were 14 (45.2%) men and 17 (54.8%) women in group 1 and 16 (57.1%) men and 12 (42.9%) women in group 2. The mean age of the subjects was 64.42 ± 5.51 years in group 1 and 62.32 ± 7.54 years in group 2. The median visual analog scale pain score was 2 (1-3) in group 1 and 4 (1-6) in group 2. The visual analog scale pain score was significantly lower in group 1 than in group 2 (p < 0.001).RESULTSThere were 14 (45.2%) men and 17 (54.8%) women in group 1 and 16 (57.1%) men and 12 (42.9%) women in group 2. The mean age of the subjects was 64.42 ± 5.51 years in group 1 and 62.32 ± 7.54 years in group 2. The median visual analog scale pain score was 2 (1-3) in group 1 and 4 (1-6) in group 2. The visual analog scale pain score was significantly lower in group 1 than in group 2 (p < 0.001).Topical 0.1% nepafenac has an additive analgesic effect when combined with topical anesthesia for intravitreal Ozurdex injection.CONCLUSIONTopical 0.1% nepafenac has an additive analgesic effect when combined with topical anesthesia for intravitreal Ozurdex injection.
Author Ogurel, Tevfik
Ozkal, Fatma
Ölmez, Yaşar
Onaran, Zafer
Ogurel, Reyhan
Örnek, Nurgül
Author_xml – sequence: 1
  givenname: Tevfik
  orcidid: 0000-0003-0658-2286
  surname: Ogurel
  fullname: Ogurel, Tevfik
  email: ogureltevfik@hotmail.com
  organization: Department of Ophthalmology, Faculty of Medicine, Kırıkkale University, Yahsihan, Turkey
– sequence: 2
  givenname: Reyhan
  surname: Ogurel
  fullname: Ogurel, Reyhan
  email: ogureltevfik@hotmail.com
  organization: Reyhan Ogurel Eye Clinic, Kırıkkale, Turkey
– sequence: 3
  givenname: Fatma
  surname: Ozkal
  fullname: Ozkal, Fatma
  organization: Department of Ophthalmology, Faculty of Medicine, Kırıkkale University, Yahsihan, Turkey
– sequence: 4
  givenname: Yaşar
  surname: Ölmez
  fullname: Ölmez, Yaşar
  organization: Adıyaman Besni State Hospital, Besni, Turkey
– sequence: 5
  givenname: Nurgül
  surname: Örnek
  fullname: Örnek, Nurgül
  organization: Department of Ophthalmology, Faculty of Medicine, Kırıkkale University, Yahsihan, Turkey
– sequence: 6
  givenname: Zafer
  surname: Onaran
  fullname: Onaran, Zafer
  organization: Department of Ophthalmology, Faculty of Medicine, Kırıkkale University, Yahsihan, Turkey
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31317125$$D View this record in MEDLINE/PubMed
BookMark eNqNks9rFDEUxwep2Fp79yQDIngZTTLJTHIRpFQtFHrRc3ibeVmzTJM1yWxt_3oz3dofCxbJIeE7n_edb97Ly2rPB49V9ZqSD5T2_UcmqJCccqpkR6XonlUHs9TM2t6D8351lNKKEMLKIl33otpvaUt7ysRBdX2ygXGC7IKv0Vo02W3QY0p1sHX50bva4xosejB1QZxfzUjwTcQRMg71Gtwslz079DnVkx8wLoPzyyLnCBuXI8JYn19PccDf9xavqucWxoRHt_th9ePLyffjb83Z-dfT489njRGiy00vTa9gIEDlwBaArSk3U1S2rKWDJart6cIIKhUAIZZ3TFFmleFW2U4otO1hdbr1HQKs9Dq6C4hXOoDTN0KISw0xOzOi5hLEYNqu53TBYcGlQCUMlxYGkEzx4kW3XpNfw9UljOOdISV6HoveHUup-bStWU-LCxwMzl0ZHwV5_MW7n3oZNrrrGOkZLQbvbw1i-DVhyvrCJYPjCB7DlDRjQqkyWK4K-nYHXYUp-tJezThrBSG0l09SbVviq16QQr15mPsu8N_HU4BuC5gYUopotXH55imVa7jxqY6QncL_aGKzLUmwxPu4_-T_AHuW8zk
CitedBy_id crossref_primary_10_1080_08164622_2021_1945412
crossref_primary_10_1097_IAE_0000000000004085
Cites_doi 10.1023/A:1007001131987
10.1111/aos.12901
10.1080/02713683.2018.1461908
10.3109/08820538.2014.889179
10.2147/OPTH.S3965
10.5301/ejo.5000147
10.1089/jop.2010.0082
10.4103/0301-4738.98705
10.1159/000448057
10.3928/15428877-20090101-05
10.1097/00006982-200512000-00007
10.2147/OPTH.S4684
10.19125/jmrd.2015.1.1.15
10.1038/eye.2014.129
10.1111/aos.12802
10.1016/j.ophtha.2005.06.009
10.2147/PPA.S46667
10.2174/157339909787314149
10.1016/S0140-6736(74)90884-8
10.1016/j.jcrs.2007.05.015
10.1016/0002-9394(73)90489-3
10.1111/j.1442-9071.1995.tb00179.x
10.1155/2018/3095961
10.1155/2015/861535
10.1016/j.jcrs.2013.07.042
10.1016/0304-3959(83)90126-4
10.1097/IAE.0b013e3182252ad3
10.1016/j.ophtha.2014.04.035
10.1177/112067210601600509
10.1111/j.1755-3768.2008.01491.x
10.1097/IAE.0b013e3181eac724
10.1089/jop.2018.0113
10.1007/s00417-007-0569-6
ContentType Journal Article
Copyright The Author(s), 2019
The Author(s), 2019. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://www.creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s), 2019 2019 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s), 2019
– notice: The Author(s), 2019. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://www.creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s), 2019 2019 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AFRWT
AAYXX
CITATION
NPM
K9.
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AYAGU
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1177/2515841419861856
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
Australia & New Zealand Database
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
Health & Medical Collection (Alumni Edition)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Australia & New Zealand Database
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
PubMed


MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 4
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2515-8414
ExternalDocumentID oai_doaj_org_article_48a5dc36741b4ab485e95c48fada8294
10.1177/2515841419861856
PMC6620721
31317125
10_1177_2515841419861856
10.1177_2515841419861856
Genre Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GroupedDBID 04C
0R~
53G
54M
7X7
8FI
8FJ
AASGM
ABQXT
ABUWG
ABVFX
ACARO
ACROE
ADBBV
ADOGD
AEWDL
AFCOW
AFKRA
AFKRG
AFRWT
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AYAGU
BCNDV
BDDNI
BENPR
BMSDO
BPHCQ
BSEHC
BVXVI
CCPQU
DC.
EBS
EIHBH
EJD
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
J8X
K.F
M~E
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
ROL
RPM
SAUOL
SCDPB
SCNPE
SFC
UKHRP
ZCN
AAYXX
ACHEB
CITATION
PUEGO
31X
3V.
AATBZ
ACGZU
ACSIQ
AEWHI
DV7
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
NPM
OK1
SFK
SFT
SGV
SPP
K9.
7XB
8FK
AZQEC
DWQXO
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c556t-78c79ad0a18d2bae3c2519183231df09371bc5189aa00f462912f9c4f9f659ef3
IEDL.DBID AFRWT
ISSN 2515-8414
IngestDate Wed Aug 27 01:24:23 EDT 2025
Tue Aug 19 19:50:05 EDT 2025
Tue Sep 30 15:37:44 EDT 2025
Fri Sep 05 06:48:09 EDT 2025
Mon Jun 30 04:21:31 EDT 2025
Sat Aug 23 14:29:42 EDT 2025
Thu Jan 02 22:54:17 EST 2025
Wed Oct 01 06:43:45 EDT 2025
Thu Apr 24 22:51:00 EDT 2025
Tue Jun 17 22:49:13 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords nepafenac
pain
intravitreal injection
Ozurdex
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
cc-by-nc
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c556t-78c79ad0a18d2bae3c2519183231df09371bc5189aa00f462912f9c4f9f659ef3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-0658-2286
OpenAccessLink https://journals.sagepub.com/doi/full/10.1177/2515841419861856?utm_source=summon&utm_medium=discovery-provider
PMID 31317125
PQID 2423500178
PQPubID 1076341
ParticipantIDs doaj_primary_oai_doaj_org_article_48a5dc36741b4ab485e95c48fada8294
unpaywall_primary_10_1177_2515841419861856
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6620721
proquest_miscellaneous_2259906649
proquest_journals_2423500178
proquest_journals_2331589750
pubmed_primary_31317125
crossref_citationtrail_10_1177_2515841419861856
crossref_primary_10_1177_2515841419861856
sage_journals_10_1177_2515841419861856
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-01-01
PublicationDateYYYYMMDD 2019-01-01
PublicationDate_xml – month: 01
  year: 2019
  text: 2019-01-01
  day: 01
PublicationDecade 2010
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: United States
– name: London
– name: Sage UK: London, England
PublicationTitle Therapeutic advances in ophthalmology
PublicationTitleAlternate Ther Adv Ophthalmol
PublicationYear 2019
Publisher SAGE Publications
Sage Publications Ltd
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: Sage Publications Ltd
– name: SAGE Publishing
References Donati, Gandolfi, Caprani 2018; 2018
Walters, Raizman, Ernest 2007; 33
Haas, Falkner-Radler, Wimpissinger 2016; 94
Huskisson 1974; 304
Stahl, Agostini, Hansen 2007; 245
Kessel, Tendal, Jørgensen 2014; 121
Zanetti, Fulco, Chaves 2012; 60
So 2015; 1
Kok, Lau, Maycock 2005; 112
Georgakopoulos, Plotas, Kagkelaris 2019; 35
Price, McGrath, Rafii 1983; 17
Rifkin, Schaal 2012; 22
Kozak, Cheng, Freeman 2005; 25
Callanan, Williams 2008; 2
Rajpal, Ross, Rajpal 2014; 8
Ke, Graff, Spellman 2000; 24
Kapoor, Wagner, Wagner 2015; 30
Klamann, Böttcher, Ackermann 2016; 236
Makri, Tsapardoni, Plotas 2018; 43
Blaha, Tilton, Barouch 2011; 31
Penfold, Gyory, Hunyor 1995; 23
Rodrigues, Grumann, Penha 2011; 27
Libondi, Jonas 2010; 88
Hariprasad, Akduman, Clever 2009; 3
Karabaş, Ozkan, Kocer 2015; 2015
Rifkin, Schaal 2012; 32
Segal, Segal-Trivitz, Nemet 2016; 94
Daily, Peyman, Fishman 1973; 76
Moisseiev, Regenbogen, Rabinovitch 2014; 28
Kaderli, Avci 2006; 16
Modi, Lehmann, Walters 2014; 40
Crawford, Alfaro, Kerrison 2009; 5
Cintra, Lucena, Da Silva 2009; 40
bibr17-2515841419861856
bibr12-2515841419861856
bibr9-2515841419861856
bibr8-2515841419861856
bibr3-2515841419861856
bibr25-2515841419861856
bibr21-2515841419861856
bibr11-2515841419861856
bibr16-2515841419861856
bibr24-2515841419861856
bibr7-2515841419861856
bibr29-2515841419861856
bibr33-2515841419861856
bibr2-2515841419861856
bibr20-2515841419861856
bibr23-2515841419861856
bibr6-2515841419861856
bibr10-2515841419861856
bibr31-2515841419861856
bibr15-2515841419861856
bibr28-2515841419861856
bibr32-2515841419861856
bibr19-2515841419861856
bibr1-2515841419861856
bibr30-2515841419861856
bibr5-2515841419861856
bibr27-2515841419861856
bibr13-2515841419861856
bibr14-2515841419861856
bibr26-2515841419861856
bibr4-2515841419861856
bibr18-2515841419861856
bibr22-2515841419861856
References_xml – volume: 43
  start-page: 1061
  year: 2018
  article-title: Analgesic effect of topical nepafenac 0.1% on pain related to intravitreal injections: a randomized crossover study
  publication-title: Curr Eye Res
– volume: 32
  start-page: 696
  year: 2012
  end-page: 700
  article-title: Factors affecting patients’ pain intensity during in office intravitreal injection procedure
  publication-title: Retina
– volume: 33
  start-page: 1539
  year: 2007
  end-page: 1545
  article-title: In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac
  publication-title: J Cataract Refract Surg
– volume: 27
  start-page: 197
  year: 2011
  end-page: 203
  article-title: Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection
  publication-title: J Ocul Pharmacol Ther
– volume: 5
  start-page: 8
  year: 2009
  end-page: 13
  article-title: Diabetic retinopathy and angiogenesis
  publication-title: Curr Diabetes Rev
– volume: 2
  start-page: 689
  year: 2008
  end-page: 692
  article-title: Topical nepafenac in the treatment of diabetic macular edema
  publication-title: Clin Ophthalmol
– volume: 35
  start-page: 168
  year: 2019
  end-page: 173
  article-title: Analgesic effect of a single drop of nepafenac 0.3% on pain associated with intravitreal injections: a randomized clinical trial
  publication-title: J Ocul Pharmacol Ther
– volume: 88
  start-page: e32
  year: 2010
  end-page: e33
  article-title: Topical nepafenac for treatment of exudative age-related macular degeneration
  publication-title: Acta Ophthalmol
– volume: 76
  start-page: 343
  year: 1973
  end-page: 350
  article-title: Intravitreal injection of methicillin for treatment of endophthalmitis
  publication-title: Am J Ophthalmol
– volume: 304
  start-page: 1127
  year: 1974
  end-page: 1131
  article-title: Measurement of pain
  publication-title: Lancet
– volume: 236
  start-page: 181
  year: 2016
  end-page: 185
  article-title: Intravitreal dexamethasone implant for the treatment of postoperative macular edema
  publication-title: Ophthalmologica
– volume: 40
  start-page: 203
  year: 2014
  end-page: 211
  article-title: Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study
  publication-title: J Cataract Refract Surg
– volume: 121
  start-page: 1915
  year: 2014
  end-page: 1924
  article-title: Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops a systematic review
  publication-title: Ophthalmology
– volume: 2015
  start-page: 861535
  year: 2015
  article-title: Comparison of two anesthetic methods for intravitreal Ozurdex injection
  publication-title: J Ophthalmol
– volume: 1
  start-page: 15
  year: 2015
  end-page: 18
  article-title: Improving patient compliance with biopharmaceuticals by reducing injection-associated pain
  publication-title: J Mucopolysacch Rare Dis
– volume: 28
  start-page: 980
  year: 2014
  end-page: 985
  article-title: Evaluation of pain during intravitreal Ozurdex injections vs. intravitreal bevacizumab injections
  publication-title: Eye (Lond)
– volume: 94
  start-page: 198
  year: 2016
  end-page: 202
  article-title: Needle size in intravitreal injections—pain evaluation of a randomized clinical trial
  publication-title: Acta Ophthalmol
– volume: 40
  start-page: 13
  year: 2009
  end-page: 18
  article-title: Comparative study of analgesic effectiveness using three different anesthetic techniques for intravitreal injection of bevacizumab
  publication-title: Ophthalmic Surg Lasers Imaging
– volume: 60
  start-page: 277
  year: 2012
  end-page: 281
  article-title: Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac, and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial
  publication-title: Indian J Ophthalmol
– volume: 22
  start-page: 1008
  year: 2012
  end-page: 1012
  article-title: Shortening ocular pain duration following intravitreal injections
  publication-title: Eur J Ophthalmol
– volume: 31
  start-page: 535
  year: 2011
  end-page: 539
  article-title: Randomized trial of anesthetic methods for intravitreal injections
  publication-title: Retina
– volume: 30
  start-page: 475
  year: 2015
  end-page: 481
  article-title: The sustained-release dexamethasone implant: expanding indications in vitreoretinal disease
  publication-title: Semin Ophthalmol
– volume: 24
  start-page: 371
  year: 2000
  end-page: 384
  article-title: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II
  publication-title: Inflammation
– volume: 16
  start-page: 718
  year: 2006
  end-page: 721
  article-title: Comparison of topical and subconjunctival anesthesia in intravitreal injection administrations
  publication-title: Eur J Ophthalmol
– volume: 245
  start-page: 1429
  year: 2007
  end-page: 1436
  article-title: Bevacizumab in retinal vein occlusion: results of a prospective case series
  publication-title: Graefes Arch Clin Exp Ophthalmol
– volume: 2018
  start-page: 3095961
  year: 2018
  article-title: Evaluation of the effectiveness of treatment with dexamethasone intravitreal implant in cystoid macular edema secondary to retinal vein occlusion
  publication-title: Biomed Res Int
– volume: 3
  start-page: 147
  year: 2009
  end-page: 154
  article-title: of cystoid macular edema with the new-generation NSAID nepafenac 0.1%
  publication-title: Clin Ophthalmol
– volume: 23
  start-page: 293
  year: 1995
  end-page: 298
  article-title: Exudative macular degeneration and intravitreal triamcinolone. A pilot study
  publication-title: Aust N Z J Ophthalmol
– volume: 17
  start-page: 45
  year: 1983
  end-page: 56
  article-title: The validation of visual analog scales as ratio scale for measures for chronic and experimental pain
  publication-title: Pain
– volume: 8
  start-page: 925
  year: 2014
  end-page: 931
  article-title: Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence
  publication-title: Patient Prefer Adherence
– volume: 112
  start-page: 1916
  year: 2005
  article-title: Outcome of intravitreal triamcinolone in uveitis
  publication-title: Ophthalmology
– volume: 94
  start-page: 203
  year: 2016
  end-page: 204
  article-title: Anxiety levels and perceived pain intensity during intravitreal injections
  publication-title: Acta Ophthalmol
– volume: 25
  start-page: 994
  year: 2005
  end-page: 998
  article-title: Lidocaine gel anesthesia for intravitreal drug administration
  publication-title: Retina
– ident: bibr14-2515841419861856
  doi: 10.1023/A:1007001131987
– ident: bibr20-2515841419861856
  doi: 10.1111/aos.12901
– ident: bibr30-2515841419861856
  doi: 10.1080/02713683.2018.1461908
– ident: bibr8-2515841419861856
  doi: 10.3109/08820538.2014.889179
– ident: bibr13-2515841419861856
  doi: 10.2147/OPTH.S3965
– ident: bibr6-2515841419861856
  doi: 10.5301/ejo.5000147
– ident: bibr22-2515841419861856
  doi: 10.1089/jop.2010.0082
– ident: bibr26-2515841419861856
  doi: 10.4103/0301-4738.98705
– ident: bibr10-2515841419861856
  doi: 10.1159/000448057
– ident: bibr18-2515841419861856
  doi: 10.3928/15428877-20090101-05
– ident: bibr16-2515841419861856
  doi: 10.1097/00006982-200512000-00007
– ident: bibr11-2515841419861856
  doi: 10.2147/OPTH.S4684
– ident: bibr29-2515841419861856
  doi: 10.19125/jmrd.2015.1.1.15
– ident: bibr7-2515841419861856
  doi: 10.1038/eye.2014.129
– ident: bibr21-2515841419861856
  doi: 10.1111/aos.12802
– ident: bibr2-2515841419861856
  doi: 10.1016/j.ophtha.2005.06.009
– ident: bibr27-2515841419861856
  doi: 10.2147/PPA.S46667
– ident: bibr3-2515841419861856
  doi: 10.2174/157339909787314149
– ident: bibr32-2515841419861856
  doi: 10.1016/S0140-6736(74)90884-8
– ident: bibr15-2515841419861856
  doi: 10.1016/j.jcrs.2007.05.015
– ident: bibr1-2515841419861856
  doi: 10.1016/0002-9394(73)90489-3
– ident: bibr5-2515841419861856
  doi: 10.1111/j.1442-9071.1995.tb00179.x
– ident: bibr9-2515841419861856
  doi: 10.1155/2018/3095961
– ident: bibr25-2515841419861856
  doi: 10.1155/2015/861535
– ident: bibr28-2515841419861856
  doi: 10.1016/j.jcrs.2013.07.042
– ident: bibr33-2515841419861856
  doi: 10.1016/0304-3959(83)90126-4
– ident: bibr23-2515841419861856
  doi: 10.1097/IAE.0b013e3182252ad3
– ident: bibr31-2515841419861856
  doi: 10.1016/j.ophtha.2014.04.035
– ident: bibr17-2515841419861856
  doi: 10.1177/112067210601600509
– ident: bibr12-2515841419861856
  doi: 10.1111/j.1755-3768.2008.01491.x
– ident: bibr24-2515841419861856
  doi: 10.1097/IAE.0b013e3181eac724
– ident: bibr19-2515841419861856
  doi: 10.1089/jop.2018.0113
– ident: bibr4-2515841419861856
  doi: 10.1007/s00417-007-0569-6
SSID ssj0002020066
Score 2.0863724
Snippet Purpose: To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection. Methods: This prospective, randomized,...
To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection. This prospective, randomized, double-blind...
Purpose:To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection.Methods:This prospective, randomized,...
Purpose: To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection. Methods: This prospective, randomized,...
To evaluate the analgesic effect of topical 0.1% nepafenac solution during intravitreal Ozurdex injection.PURPOSETo evaluate the analgesic effect of topical...
SourceID doaj
unpaywall
pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2515841419861856
SubjectTerms Age
Analgesics
Anesthesia
Diabetes
Diabetic retinopathy
Disease
Drug delivery systems
Edema
Eye surgery
Injections
Macular degeneration
Nonsteroidal anti-inflammatory drugs
Original Research
Pain
Womens health
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELZQD8AF8WahICMBEkir7Pq19hFQqwqpcKFSb6ux14ZUkRO1CY_-esa77iaBQi9cbSeZHc_kG-_MfCbkRVMF5pgNZSXAlMIZU4Lloqw1qMBAVs6l9x2HH9XBkfhwLI83rvpKNWEDPfCguInQIDvHFSKfFWCFlt5IJ3SADjQzPRMowtjGYeqkT6_1SYV1XnKCOI5YWws8ZCvEKLWFQz1d_2Ux5p-lkrkZ_8YqLuDnd5jNNuBo_za5leNI-naQ_w655uNdcv0wZ8rvkfO9kcabDjUb-W-NzgNFYV_SiEAUfARHcck0nvQ1WbHsm1t8RxcwTcM0E6-e0dRtdvpljlCHwyjlt2kqUp_RT-epE-LH-ivuk6P9vc_vD8p8z0LppFTLstGuMdBVUOuOWfDcpXbW5Ou87kKVGPOsk7U2AFUVhGKmZsE4EUxQ0vjAH5CdOI_-EaENejRuluZBGmF1ZRsRBFeAx8xgRdMUZHKh9dZlEvJ0F8asrTPv-O_7VJDX4ycWAwHHP9a-Sxs5rkvU2f0AGlSbDaq9yqAKsnthBm3257OWcY4_ZTC8unwag1KZAF8X5Pk4jY6asi8Q_XyFa_CgadAmhSnIw8GoRkF5jWEchpoFabbMbetJtmfi9GtPBq4USxR3BXmVDHMt0t919GY03SsV-vh_KPQJuYlRphneW-2SneXpyj_FSG5pn_VO-wugSz-K
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3di9QwEA96gvoifls9JYIKCmXb5vtJVO44hNMXD_atJGlzrizpuh9-3F_vTDfbdfU8X5O0nSYzmclk5jeEPFNFqHzlQl5wa3LujcmtYzwvtZWhsqLwHv0dxx_k0Ql_Pxbj5HBbpLDKzZ7Yb9RN59FHPkK9L_pi8q9nX3OsGoW3q6mExmVypQRTBblajdXgY4GDParU7e3kCLQ5aNySw1FbgqaSO9qoB-0_z9L8O2AypeRfW8WZ_fndTqe_KaXDm-RGsibpm_Xy3yKX2nibXD1O9-V3yNnBAOZN15EbaXOjXaBA7HMaQR2FNlpPYcgkfukjs2Lep7i0DZ3ZCTbTBL-6oJhzNj_tQOFBM1D5bYKh6lP68QzzIX5sX3GXnBwefHp3lKdqC7kXQi5zpb0ytilsqZvK2ZZ5TGpFiWdlEwrEzXNelNpYWxSBy8qUVTCeBxOkMG1g98he7GL7gFAFcu2Z1CwIw50unOKBM2nhsBkcVyojo82s1z5BkWNFjGldJvTxP9cpIy-HJ2ZrGI4Lxr7FhRzGIYB239DNT-skjzXXVjRAIxhUjlvHtWiN8FwH21hdGZ6R_Q0b1EmqF3XFGHzKgJF1fvfAohl5OnSDuOIdjI1tt4IxcNw0wJPcZOT-mqkGQlkJxhwYnBlRO-y28ye7PXHyuYcEl7JCoLuMvEDG3JL07zl6NbDufyf04cU_-4hcByvSrP1S-2RvOV-1j8FSW7onvTj-AjRiNsk
  priority: 102
  providerName: ProQuest
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELegk2AvfDMCAxkJkEDKmsQfsR8H2jQhbfBApfEUOU48CpVb9YOP_vXcJW5KtwGCV_uS2tez7-fc3c-EPMsTl9msdHHCjY651To2JeNxqox0mRGJtfi94_hEHg3421NxGnJzsBYmaHC2h2lVMKJms8bVPalcP8QY--CTwW-mHA7MEvyNvEq2JMaXemRrcPJ-_yNeKAciMcqsQ5MXHttwRQ1j_2Uw82K2ZKjHv77wE_PjmxmNfvFIhzfba1dnDZEhJqJ82VvMYRrLczSP_z3ZW-RGwKp0vzWu2-RK7e-Qa8chGn-XLA86qnDa5oWErZOOHYX3PqcenJ2rvbEURIb-c5P35eOmgKau6MQMsZkGctcZxYq26dkY3Ck0gxq-DjERfkTfLbHa4vv6FffI4PDgw5ujONzlEFsh5DzOlc21qRKTqiorTc0slszifsLSyiXIyldakSptTJI4LjOdZk5b7rSTQteO3Sc9P_b1A0Jz2DUsk4o5oXmpkjLnjjNp4CjrSp7nEemv_tbCBqJzvG9jVKSB2_y8SiPysnti0pJ8_EH2NVpKJ4f03E3DeHpWhNVecGVEBWMEuFZyU3Ilai0sV85URmWaR2R3ZWfFygiKjDH4KQ0Q7vJuAL4CQYWKyNOuGzYDjPAYX48XIAOHWQ0gkuuI7LRW2w2UpQAVAc5GJN-w542ZbPb44aeGcFzKDGn0IvICDXU9pN_r6FW3Nv6q0If_IvyIbANi1e03sF3Sm08X9WNAhfPySVj7PwHxCFXA
  priority: 102
  providerName: Unpaywall
Title Evaluation effectiveness of 0.1% nepafenac on injection-related pain in patients undergoing intravitreal Ozurdex injection
URI https://journals.sagepub.com/doi/full/10.1177/2515841419861856
https://www.ncbi.nlm.nih.gov/pubmed/31317125
https://www.proquest.com/docview/2331589750
https://www.proquest.com/docview/2423500178
https://www.proquest.com/docview/2259906649
https://pubmed.ncbi.nlm.nih.gov/PMC6620721
https://journals.sagepub.com/doi/pdf/10.1177/2515841419861856
https://doaj.org/article/48a5dc36741b4ab485e95c48fada8294
UnpaywallVersion publishedVersion
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2515-8414
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002020066
  issn: 2515-8414
  databaseCode: DOA
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2515-8414
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002020066
  issn: 2515-8414
  databaseCode: M~E
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2515-8414
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002020066
  issn: 2515-8414
  databaseCode: RPM
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Australia & New Zealand Database
  customDbUrl:
  eissn: 2515-8414
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002020066
  issn: 2515-8414
  databaseCode: AYAGU
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/anz
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2515-8414
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002020066
  issn: 2515-8414
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2515-8414
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002020066
  issn: 2515-8414
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVSPB
  databaseName: Sage Journals GOLD Open Access 2024
  customDbUrl:
  eissn: 2515-8414
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002020066
  issn: 2515-8414
  databaseCode: AFRWT
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: http://journals.sagepub.com/
  providerName: SAGE Publications
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3rb9MwELe2TgK-IN4ERhUkQAIpNA_bsT-hDrWakFamaRXjU-Q48Sjq3Kprge2v5y5xUsrG41MU24kvztl3vsfPhLxIQxPrODdBSJUMqJYyUHlCg0gobmLFQq3R3nEw4vtj-uGEnWwR2-TCuBE8f4thVUBRtVjj7EZrdM85GXsglEFwRhR2zBwEDn-3Wp5ltbW7OVQDS9A9vTpDz7bGeMiLoMlu2yY7iFzOOmSnPzz6dNxaZeKwckbgiXTQRYB9rH2bV7rdkGUV5P91eurVcEuX0H9zZefq4ruaTn8RacM75LbTRf1-zTx3yVZp75EbB87bfp9cDloocL-O-3BLoz8zPhD70rcgzExplfahycR-reK6bFAlyJSFP1cTLPYdeOu5jxlri9MZiEsoBiq_TTDQfep_vMRsih_rVzwg4-Hg-P1-4M5qCDRjfBmkQqdSFaGKRBHnqkw0psTiepFEhQkRdS_XLBJSqTA0lMcyio3U1EjDmSxN8pB07MyWj4mfwqqgEy4SwyTNRZin1NCEK9iqmpymqUd6zahn2gGZ43ka0yxy2OW__yePvG6fmNcgHn9pu4c_sm2H8NtVwWxxmrnZnFGhWAE0gjqWU5VTwUrJNBVGFUrEknpkt2GDrOHoLE4S6EqCinZ9NSi2DJUG4ZHnbTVMdvTgKFvOVtAGNqsS-JNKjzyqmaolNIlAFQR11SPpBrttfMlmjZ18qQDFOY8RJs8jr5Ax1yT9eYzetKz7zwF98r9vfUpugTYqa_vWLuksF6vyGWh8y7xLttOTtOsmK1z3BqPDo25lP4G78eiw__knzqxRIg
linkProvider SAGE Publications
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlEuiDeBAkaiSCBFm_iV-IAQj1Zb2i2XVtpbcJy4LFolyz4o7Y_iNzLOa1ko5dSr7fVO7PHM2DPzDcDzKLDU0NT6AdfK50YpX6eM-2GspaVaBMa4947Bgewf8Y9DMVyDn20ujAurbGViJaiz0rg38p7T-6IqJv9m8s13VaOcd7UtoVGzxV5-eoJXttnr3Q-4v1uU7mwfvu_7TVUB3wgh534Um0jpLNBhnNFU58y45E3H2SzMbODw4VIjwlhpHQSWS6pCapXhVlkpVG4ZznsFrnIWcIfVHw2j7k2HBpUrY-kN7eHUqOFDjld7iZpRrmi_qkjAeZbt3wGaDQTAxqKY6NMTPR7_pgR3bsKNxnolb2t2uwVreXEbrg0a__wdONvuwMNJHSnSCFNSWoLEbpEC1Z_NC20IDhkVX6tIsMKvUmryjEz0yDWTBu51RlyO2_S4RAWLzUjl95ELjR-TT2cu_-LHcoq7cHQp-3AP1ouyyB8AiVCOGCZjZoXiaRykEbecSY2XW5vyKPKg1656Yhroc1eBY5yEDdr5n_vkwcvuF5Ma9uOCse_cRnbjHGB31VBOj5Pm_Cc81iJDGtGAS7lOeSxyJQyPrc50TBX3YLNlg6SRIrOEMoZ_pdCoO7-7OxIePOu6UTw4n48u8nKBY_B6q5AnufLgfs1UHaEsROMRDVwPohV2W_mS1Z5i9KWCIJeSOmA9D144xlyS9O81etWx7n8X9OHFH_sUNvqHg_1kf_dg7xFcRwtW1W9im7A-ny7yx2glztMn1dEk8PmyZcEv0O9ywQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zb9QwELaglQoviJtAASMBEkjpJvER-7FAV-VoQagVfYscJy6LVs5qu8vRX89M4s2ytByvvjJxZjKf7ZnPhDzOE5fZrHRxwo2OudU6NiXjcaqMdJkRibW437G3L3cP-ZsjcRRiczAXJszgyRaGVYFE7c8arXtSuUE4YxyATwa_mXJYMEvwN_IiWYdVTQ5Kvb49_PjpoN9kgZU9-lS8YA66xNhneVR5ZpgV19Qy-J8HO89GT4b8_EtzPzE_vpnx-BcPNbxKrgRoSbc7XbhGLtT-OtnYC4fnN8jpTs_sTbswjvCno42jIOwT6sE3udobS6HJyH9pw7R83Oa71BWdmBEW08DFekIxAW163ID3g2KQ8usI49bH9P0pJkd8Xw5xkxwOdw5e7sbh6oXYCiFnca5srk2VmFRVWWlqZjHDFc2fpZVLkESvtCJV2pgkcVxmOs2cttxpJ4WuHbtF1nzj6zuE5mDklknFnNC8VEmZc8eZNLDydCXP84gMFrNe2MBLjtdjjIs0UJH__p0i8qzvMek4Of7S9gV-yL4dsmm3Bc30uAjGWXBlRAUyAroquSm5ErUWlitnKqMyzSOyuVCDYqGgRcYYPEoD4jq_GnCqQAygIvKorwbbxQMZ4-tmDm1g7alBP7mOyO1OqXpBWQrIDtBnRPIVdVt5k9UaP_rc8oNLmSHrXUSeomIuRfrzHD3vVfefE3r3f0d9SDY-vBoW717vv71HLgPO1N3O1SZZm03n9X3AcrPyQbDYnz1qOoI
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELegk2AvfDMCAxkJkEDKmsQfsR8H2jQhbfBApfEUOU48CpVb9YOP_vXcJW5KtwGCV_uS2tez7-fc3c-EPMsTl9msdHHCjY651To2JeNxqox0mRGJtfi94_hEHg3421NxGnJzsBYmaHC2h2lVMKJms8bVPalcP8QY--CTwW-mHA7MEvyNvEq2JMaXemRrcPJ-_yNeKAciMcqsQ5MXHttwRQ1j_2Uw82K2ZKjHv77wE_PjmxmNfvFIhzfba1dnDZEhJqJ82VvMYRrLczSP_z3ZW-RGwKp0vzWu2-RK7e-Qa8chGn-XLA86qnDa5oWErZOOHYX3PqcenJ2rvbEURIb-c5P35eOmgKau6MQMsZkGctcZxYq26dkY3Ck0gxq-DjERfkTfLbHa4vv6FffI4PDgw5ujONzlEFsh5DzOlc21qRKTqiorTc0slszifsLSyiXIyldakSptTJI4LjOdZk5b7rSTQteO3Sc9P_b1A0Jz2DUsk4o5oXmpkjLnjjNp4CjrSp7nEemv_tbCBqJzvG9jVKSB2_y8SiPysnti0pJ8_EH2NVpKJ4f03E3DeHpWhNVecGVEBWMEuFZyU3Ilai0sV85URmWaR2R3ZWfFygiKjDH4KQ0Q7vJuAL4CQYWKyNOuGzYDjPAYX48XIAOHWQ0gkuuI7LRW2w2UpQAVAc5GJN-w542ZbPb44aeGcFzKDGn0IvICDXU9pN_r6FW3Nv6q0If_IvyIbANi1e03sF3Sm08X9WNAhfPySVj7PwHxCFXA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+effectiveness+of+0.1%25+nepafenac+on+injection-related+pain+in+patients+undergoing+intravitreal+Ozurdex+injection&rft.jtitle=Therapeutic+advances+in+ophthalmology&rft.au=Ogurel%2C+Tevfik&rft.au=Ogurel%2C+Reyhan&rft.au=Ozkal%2C+Fatma&rft.au=%C3%96lmez%2C+Ya%C5%9Far&rft.date=2019-01-01&rft.pub=SAGE+Publications&rft.issn=2515-8414&rft.eissn=2515-8414&rft.volume=11&rft_id=info:doi/10.1177%2F2515841419861856&rft.externalDocID=10.1177_2515841419861856
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2515-8414&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2515-8414&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2515-8414&client=summon